What is Medtronic?
Medical technology company with $33.537B of FY2025 revenue and enterprise healthcare scale.
- Category
- Medical technology
- Headquarters
- Dublin, Ireland / Minneapolis, MN
- Founded
- 1949
- Employees
- 95,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: MDT; ~$110B market cap
What is Medtronic?
Medtronic is a public medical technology company headquartered in Dublin, Ireland / Minneapolis, MN. It reported $33.537B of FY2025 revenue and operates at global enterprise scale.
Medtronic operates in medical technology with a portfolio spanning Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. The company reported $33.537B of FY2025 revenue, employs about 95,000+, and trades as NYSE: MDT. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Medtronic is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, Medtronic is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does Medtronic offer?
Medtronic offers healthcare products and services across Cardiovascular, Medical Surgical, Neuroscience, and Diabetes.
- Cardiovascular devices· Cardiovascular
- Surgical and medical-surgical· Medical Surgical
- Neuroscience devices· Neuroscience
- Diabetes pumps and sensors· Diabetes
- Patient monitoring· Monitoring
- Surgical robotics· Surgery
- Implantable therapies· Implants
How does Medtronic make money?
Medtronic sells implantable devices, disposables, capital equipment, monitoring systems, diabetes technology, service, and procedural support through hospital, physician, payer, distributor, and tender channels.
Medtronic sells implantable devices, disposables, capital equipment, monitoring systems, diabetes technology, service, and procedural support through hospital, physician, payer, distributor, and tender channels. In FY2025, that model produced $33.537B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is device-, procedure-, tender-, geography-, reimbursement-, service-, and group-purchasing driven; implantable products and capital systems are contracted rather than sold in public tiers. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads Medtronic?
Medtronic is led by Geoff Martha, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Geoff MarthaChairman and Chief Executive OfficerCEO since 2020Leads the global medtech portfolio and portfolio-management program.
- Thierry PiétonExecutive Vice President and Chief Financial OfficerCFO in 2026Finance leader appearing with Martha in 2026 investor presentations.
- Rogerio BrancoSVP and Chief Operations and Supply Chain OfficerSenior executive leadershipRuns manufacturing, quality supply, and global operations priorities.
- Scott CundySVP and Chief Quality, Development, and Innovation OfficerSenior executive leadershipOversees quality, product development, and innovation systems.
How do you contact Medtronic's leadership?
Medtronic publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investor.relations@medtronic.com) or official contact forms rather than guessed personal addresses.
investor.relations@medtronic.com is a public investor/contact route; personal executive email format not verifiedHow much funding has Medtronic raised?
Medtronic is a mature public company, not a venture-backed startup. It trades as NYSE: MDT, had an approximate ~$110B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
Medtronic's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1949, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported $33.537B of FY2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: Medtronic has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did Medtronic get here?
Medtronic grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1949Medtronic foundedEarl Bakken and Palmer Hermundslie start the company in Minnesota.
- 1960Implantable pacemaker eraMedtronic becomes associated with cardiac pacing innovation.
- 2015Covidien acquisition closesMedtronic becomes a larger global medtech company and redomiciles to Ireland.
- 2021Hugo robotic-assisted surgery launches commerciallyMedtronic expands surgical robotics.
- 2025$33.537B FY25 revenueMedtronic reports organic growth across major segments.
- 2026Investor focus on portfolio actionsManagement continues shareholder-value and strategic-priority work.
Who are Medtronic's competitors?
Medtronic competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- AbbottCompetes in cardiovascular, diabetes, neuromodulation, and diagnostic-adjacent markets.
- Boston ScientificInterventional cardiology, rhythm, endoscopy, urology, and neuromodulation competitor.
- Johnson & Johnson MedTechSurgery, orthopaedics, electrophysiology, and interventional competitor.
- StrykerSurgical, spine, neurotechnology, and orthopaedic competitor.
- Intuitive SurgicalRobotic surgery competitor around procedural automation and operating-room budgets.
Medtronic — frequently asked questions
